Evidence map›Paper›PMID 27371173›Full record

ArticleJournal of neuroinflammation2016

Characterization of the binding pattern of human aquaporin-4 autoantibodies in patients with neuromyelitis optica spectrum disorders.

Friederike Tuller, Hannah Holzer, Kathrin Schanda, Fahmy Aboulenein-Djamshidian, Romana Höftberger, Michael Khalil, Thomas Seifert-Held, Fritz Leutmezer, Thomas Berger, Markus Reindl

Open access · goldAbstract read
In one paragraph

Article in Journal of neuroinflammation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.5field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Friederike TullerClinical Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.
Hannah HolzerClinical Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.
Kathrin SchandaClinical Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.
Fahmy Aboulenein-DjamshidianDepartment of Neurology, Karl Landsteiner Institute for Neuroimmunological and Neurodegenerative Disorders, Sozialmedizinisches Zentrum Ost Donauspital, Vienna, Austria.
Romana HöftbergerInstitute of Neurology, Medical University of Vienna, Vienna, Austria.
Michael KhalilDepartment of Neurology, Medical University of Graz, Graz, Austria.
Thomas Seifert-HeldDepartment of Neurology, Medical University of Graz, Graz, Austria.
Fritz LeutmezerDepartment of Neurology, Medical University of Vienna, Vienna, Austria.
Thomas BergerClinical Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.
Markus ReindlClinical Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria. Markus.Reindl@i-med.ac.at.ORCID 0000-0003-2817-1402
Innsbruck Medical University · ATMedical University of Graz · ATMedical University of Vienna · ATDonauspital · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe discovery of a highly specific antibody against the aquaporin-4 (AQP4) water channel (AQP4-IgG) unified the spectrum of neuromyelitis optica spectrum disorders (NMOSD), which are considered to be antibody-mediated autoimmune diseases. The AQP4 water channel is located on astrocytic end-feet processes and consists of six transmembrane helical domains forming three extracellular loops A, C, and E in which defined amino acids were already proven to be critical for AQP4-IgG binding. However, the clinical relevance of these findings is unclear. Therefore, we have characterized the epitope specificity of AQP4-IgG-positive NMOSD patients.

methodsWe established a cell-based flow cytometry assay for the quantitative detection of AQP4-IgG-positive serum samples. Human embryonic kidney (HEK) cells were transiently transfected with an EmGFP-tagged AQP4-M23, AQP4-M1, or six AQP4-M23 extracellular loop mutants including two mutations in loop A (serial AA substitution, insertion of a myc-tag), two in loop C (N153Q, insertion of a myc-tag), and two in loop E (H230G, insertion of a myc-tag). Fourty-seven baseline and 49 follow-up serum samples and six paired cerebrospinal fluid (CSF) baseline samples of 47 AQP4-IgG-positive Austrian NMOSD patients were then tested for their binding capability to AQP4-M1 and AQP4-M23 isoforms and these six extracellular loop mutants.

resultsOverall, we could identify two broad patterns of antibody recognition based on differential sensitivity to mutations in extracellular loop A. Pattern A was characterized by reduced binding to the two mutations in loop A, whereas pattern B had only partial or no reduced binding to these mutations. These two patterns were not associated with significant differences in demographic and clinical parameters or serum titers in this retrospective study. Interestingly, we found a change of AQP4-IgG epitope recognition pattern in seven of 20 NMOSD patients with available follow-up samples. Moreover, we found different binding patterns in five of six paired CSF versus serum samples, with a predominance of pattern A in CSF.

conclusionsOur study demonstrates that AQP4-IgG in sera of NMOSD patients show distinct patterns of antibody recognition. The clinical and diagnostic relevance of these findings have to be addressed in prospective studies.

Indexed as

AdultAgedAquaporin 4AutoantibodiesEpitope MappingEpitopesFemaleFlow CytometryHEK293 CellsHumansMaleMiddle AgedModels, MolecularMutagenesisMutationNeuromyelitis OpticaAQP4 protein, humanAquaporin 4AutoantibodiesEpitopesProtein IsoformsAquaporin-4AutoantibodiesEpitope specificityFlow cytometryNeuromyelitis optica spectrum disorders

Identifiers

PMID27371173
PMCPMC4930584
OpenAlexW2474943180

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.